Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection

Covid19 Clinical Trial

Official title:

Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04508439
• Other study ID #: NR-CEI-HRAEI-19-2020
• Status: Recruiting
• Phase: N/A
• Start date: June 20, 2020
• Est. completion date: December 30, 2020

Study information

• Verified date: August 2020
• Source: Hospital Regional de Alta especialidad de Ixtapaluca
• Contact: Omar Ramos-Peñafiel, MD, PhD
• Phone: +525523351588
• Email: christian.ramos.penafiel[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms. Multiple pathogenic mechanisms are involved, including endothelial dysfunction, increased von Willebrand factor, Toll receptor activation, and tissue factor pathway activation. D-dimer levels greater than 1000 ng / mL are associated with an 18-fold increased risk of mortality. In this context, many patients may require prophylaxis or antithrombotic treatment with low molecular weight heparins. Currently, there is no validated scheme on the dose and timing of the use of antithrombotic drugs.

The study aims to identify the effect of two anticoagulant strategies (prophylactic and therapeutic) on the progression to ventilatory support or death in patients with COVID-19 infection who require hospital care.

Description:

Randomized clinical trial in patients with a confirmed infection by COVID-19 who require hospital treatment and subsequent ambulatory surveillance.

Study population. Patients with a diagnosis by PCR of COVID 19, over 18 years of age from the High Specialty Hospital of Ixtapaluca, who meet the inclusion criteria.

Statistic analysis. The student's T-test was carried out to identify the difference in the means of the quantitative variables between the groups. A value of P ≤ 0.05, 95% CI will be considered significant. For the hypothesis test, the chi-square test will be performed, considering a p≤ 0.05, 95% CI value to be significant.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: December 30, 2020
• Est. primary completion date: August 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with a diagnosis of COVID-19 infection confirmed by polymerase chain reaction test (RQ-PCR) requiring hospital care for the administration of supplemental oxygen

Exclusion Criteria:

• Patients with life expectancy less than 48hrs

• Patients who require ventilatory support upon admission

• Age over 75 years or with a history of atrial fibrillation

• History of venous or arterial thrombosis

• Severe neurological impairment

• Absence of a primary caregiver to supervise the administration of medication

• History of cerebral hemorrhage

• History of previous use of oral anticoagulants

• History of major surgery 30 days prior to admission

• Uncontrolled systemic arterial hypertension

• KDIGO stage III chronic kidney disease or less

• Hemodialysis or peritoneal dialysis treatment

• History of active or inactive cancer

• Pregnant or postpartum patients

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Coagulation Disorder
• Covid19
• Embolism
• Hemostatic Disorders
• Pneumonia
• Pulmonary Embolism

Intervention

Drug:
• Enoxaparin
Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.

Locations

Country	Name	City	State
Mexico	Hospital Regional de Alta Especialidad de Ixtapaluca	Mexico City	Ixtapaluca

Sponsors (1)

Lead Sponsor	Collaborator
Hospital Regional de Alta especialidad de Ixtapaluca

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	low molecular weight heparin (enoxaparin) and ventilatory support time	Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on ventilatory support time in patients requiring hospital care for COVID-19 infection.	30 days
Primary	thrombotic complications and Rivaroxaban	To compare oral anticoagulation therapy by administering Rivaroxaban 10mg PO every 24 hours on early thrombotic complications	30 days
Primary	low molecular weight heparin (enoxaparin) and length of hospital stay	Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the length of hospital stay in patients requiring hospital care for COVID-19 infection.	30 days
Primary	low molecular weight heparin (enoxaparin) and mortality rate	Identify the benefit of different doses of low molecular weight heparin (enoxaparin) over mortality rate in patients requiring hospital care for COVID-19 infection.	30 days